These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Moskovitz J; Moy J; Ferris RL Curr Oncol Rep; 2018 Mar; 20(2):22. PubMed ID: 29502288 [TBL] [Abstract][Full Text] [Related]
5. [Clinical research on immune checkpoint and head and neck squamous cell carcinoma]. Yu D; Qi XM; Zhao X; Liu Y; Xue K; Jin CS; Wen LJ Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):717-720. PubMed ID: 28910901 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Head and Neck Cancer. Sim F; Leidner R; Bell RB Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002 [TBL] [Abstract][Full Text] [Related]
7. The biology of combination immunotherapy in recurrent metastatic head and neck cancer. Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022 [TBL] [Abstract][Full Text] [Related]
9. Profiles of immune cell infiltration in head and neck squamous carcinoma. Liang B; Tao Y; Wang T Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32095823 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma. Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374 [TBL] [Abstract][Full Text] [Related]
11. Things are changing for head and neck squamous cell carcinomas. Guigay J Curr Opin Oncol; 2019 May; 31(3):121. PubMed ID: 30985495 [No Abstract] [Full Text] [Related]
13. Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. Merlano MC; Denaro N; Garrone O Curr Opin Oncol; 2020 May; 32(3):203-209. PubMed ID: 32195680 [TBL] [Abstract][Full Text] [Related]
14. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799 [TBL] [Abstract][Full Text] [Related]
16. Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy. Chen JL; Chang CC; Huang YS; Kuo HY; Chen TY; Wang CW; Kuo SH; Lin YL PLoS One; 2018; 13(8):e0202224. PubMed ID: 30096190 [TBL] [Abstract][Full Text] [Related]
17. Association between APOBEC3H-Mediated Demethylation and Immune Landscape in Head and Neck Squamous Carcinoma. Liu Q; Luo YW; Cao RY; Pan X; Chen XJ; Zhang SY; Zhang WL; Zhou JY; Cheng B; Ren XY Biomed Res Int; 2020; 2020():4612375. PubMed ID: 32775421 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. Moskovitz JM; Moy J; Seiwert TY; Ferris RL Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203 [TBL] [Abstract][Full Text] [Related]
19. The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. Liao P; Wang H; Tang YL; Tang YJ; Liang XH Front Immunol; 2019; 10():2457. PubMed ID: 31708918 [TBL] [Abstract][Full Text] [Related]
20. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. Chandrasekara S; Davis S; Thomson P; Haydon A Asia Pac J Clin Oncol; 2018 Oct; 14(5):e442-e447. PubMed ID: 29345108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]